Over the past several years, multiple myeloma treatment options have expanded widely for patients, resulting in significantly improved outcomes. The FDA approved around 16 new agents and 30 treatment regimens, transforming the multiple myeloma treatment paradigm for patients with newly diagnosed and relapsed/refrac...
Find MoreStep aside, CAR-Ts; with three FDA approvals, the class of bispecific antibodies has begun to take on the relapsed/refractory multiple myeloma treatment segment. Currently, the US Food and Drug Administration (FDA) has authorized 10 bispecific antibodies and one bispecific molecule, the majority of which are a...
Find MoreMultiple myeloma is the second most prevalent blood cancer diagnosis in the United States, after non-Hodgkin lymphoma. Males are significantly more likely than females to have multiple myeloma. Myeloma incidence is highly tied to age, with older adults having the highest incidence rates and being diagnosed most fre...
Find MoreOver the years, REVLIMID has become an integral weapon in the cancer therapeutics’ armory. This odyssey of REVLIMID in the multiple myeloma segment began in 2005, when it was approved by the US FDA for the treatment of adult patients with multiple myeloma, in combination with dexamethasone. As the wise say...
Find MoreThe innovation in the oncology drug pipeline has resulted in a record number of FDA and EU approvals in recent years, as investigators and sponsors seek new and targeted treatments for individuals diagnosed with different types of cancers each year. In 2022, regulators will continue to evaluate new oncology therapi...
Find MoreThe Multiple Myeloma Market is expected to grow during the study period 2017-30 due to a rich and robust pipeline, increasing incidence, and higher demand for novel therapies. A cancer of plasma cells, a malignant plasma cell dyscrasia, Multiple Myeloma (MM) is a cancer that accumulates in the bone marrow leadi...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.